MedTrace Logo

Neoadjuvant GW572016 to Treat Breast Cancer

NCT00206427 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2021-09-29

Study results available
· View outcomes & findings →

Summary

We want to learn whether GW572016 is effective in breast cancers that have HER2.

Conditions

Interventions

DRUG

GW572016

Lapatinib, 500 mg

DRUG

lapatinib

Lapatinib 500 mg PO

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Baylor Breast Care Center

    lead OTHER

Principal Investigators

  • Mothaffar Rimawi, MD · Baylor Breast Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-31
Primary Completion
2011-06-30
Completion
2012-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00206427 on ClinicalTrials.gov